These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26614378)

  • 1. Clinical Trial Design in Neuroendocrine Tumors.
    Halperin DM; Yao JC
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):209-17. PubMed ID: 26614378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of clinical trials in gastroenteropancreatic neuroendocrine tumours.
    Walter T; Krzyzanowska MK
    Neuroendocrinology; 2012; 96(3):238-48. PubMed ID: 22414794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
    Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
    Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal Bayesian design for patient selection in a clinical study.
    Buzoianu M; Kadane JB
    Biometrics; 2009 Sep; 65(3):953-61. PubMed ID: 19021600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endpoints in cancer clinical trials.
    Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
    J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure.
    Brozek JL; Guyatt GH; Schünemann HJ
    Health Qual Life Outcomes; 2006 Sep; 4():69. PubMed ID: 17005037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding clinical trial outcomes: design, analysis, and interpretation.
    Jacobe HT; Leitenberger JJ; Bergstresser PR
    Dermatol Ther; 2007; 20(2):77-85. PubMed ID: 17537135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positive clinical trials: understand the control group before implementing the result.
    Parshuram CS; Kavanagh BP
    Am J Respir Crit Care Med; 2004 Aug; 170(3):223-6. PubMed ID: 15151921
    [No Abstract]   [Full Text] [Related]  

  • 9. Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
    Mitry E; Walter T; Baudin E; Kurtz JE; Ruszniewski P; Dominguez-Tinajero S; Bengrine-Lefevre L; Cadiot G; Dromain C; Farace F; Rougier P; Ducreux M
    Eur J Cancer; 2014 Dec; 50(18):3107-15. PubMed ID: 25454413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life research.
    Lipman EL; Boyle MH
    Am J Psychiatry; 2003 Feb; 160(2):387; author reply 387. PubMed ID: 12562598
    [No Abstract]   [Full Text] [Related]  

  • 11. Time to first recurrence as a trial endpoint: time to change?
    Mehra R
    Card Electrophysiol Rev; 2003 Sep; 7(3):280-4. PubMed ID: 14739728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
    Faivre S; Sablin MP; Dreyer C; Raymond E
    Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic strategies for neuroendocrine liver metastases.
    Frilling A; Clift AK
    Cancer; 2015 Apr; 121(8):1172-86. PubMed ID: 25274401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Principles and pitfalls of clinical trials design.
    Jeffcoat MK
    J Periodontol; 1992 Dec; 63(12 Suppl):1045-51. PubMed ID: 1479524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [How to determine outcomes for clinical studies].
    Puhan MA; Klaghofer R
    Ther Umsch; 2007 Dec; 64(12):667-71. PubMed ID: 18581914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial end points in malignant glioma: need for effective trial design strategy.
    Brada M; Yung WK
    Semin Oncol; 2000 Jun; 27(3 Suppl 6):11-9. PubMed ID: 10866345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endpoints for clinical trials and revised assessment in neuro-oncology.
    Butowski N; Chang SM
    Curr Opin Neurol; 2012 Dec; 25(6):780-5. PubMed ID: 23007010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of health-related quality of life in prescribing research. Part 2: methodological considerations for the assessment of health-related quality of life in clinical trials.
    Calvert MJ; Freemantle N
    J Clin Pharm Ther; 2004 Feb; 29(1):85-94. PubMed ID: 14748903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addressing the challenges of transforming laboratory advances into Alzheimer's Disease treatments.
    Karlawish JH; Clark CM
    Neurobiol Aging; 2002; 23(6):1043-9. PubMed ID: 12470801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations when designing a clinical trial of haematopoietic stem cell transplantation for autoimmune disease.
    Bredeson CN; Pavletic SZ
    Best Pract Res Clin Haematol; 2004 Jun; 17(2):327-43. PubMed ID: 15302344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.